Citations

Clear

4847 citation(s) found for "Yu, Eric".

Abstract: Comparison of Tumor Recurrence in Oncoplastic Pelvic Reconstruction with Vertical Rectus Abdominis Musculocutaneous (VRAM) versus Omental Flaps: Outcomes Following Ablative Abdominoperineal Resection (APR) and Pelvic Exenteration
Chaudhry, Arif, Larson, David R., Tran, Nho V. , Dozois, Eric J. , Nelson, Heidi D , Manrique, Oscar J. , Oliver, Jeremie D. , Vyas, Krishna S. , Larson, David

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 26, 2018 | Volume: 6 | Issue: 9S | Pages: 78-78

10.1097/01.gox.0000546923.71186.66 Get It

Case-Based Learning in Translational Biomedical Research Education: Providing Realistic and Adaptive Skills for Early-Career Scientists
Greenberg, Alexandra J. , Campbell, Katherine , Klee, Eric W. , Staff, Nathan P. , Schimmenti, Lisa A. , Weavers, Karen M. , Ekker, Stephen C. , Windebank, Anthony J. , Greenberg-Worisek, Alexandra J, Ekker, Stephen C , Staff, Nathan P , Schimmenti, Lisa A

Mayo Clinic

Academic Medicine | September 26, 2018 | Volume: 94 | Issue: 2 | Pages: 213-216

10.1097/acm.0000000000002470 | PMID 30256254 Get It

Problem Case-based learning is an established means of educating students in law, business, and medicine; however, this methodology is not often applied to educating translational biomedical researchers. The application of case-based learning to translational biomedical research education allows scholars to actively engage with real-world material and apply their newfound knowledge as it is acquired. Approach Through the Mayo Clinic Center for Clinical and Translational Science (CCaTS), three courses were delivered in 2009–2017 which emphasized case-based learning in clinical and translational science, entrepreneurship, and individualized medicine. Quantitative measures collected in student course reviews upon course completion were analyzed. Additionally, products arising from each course were identified, including publications and startups pitched. Outcomes Analyses demonstrate that case-based learning techniques are well suited to graduate biomedical research education. Furthermore, case studies can be employed throughout the entire clinical and translational spectrum, from basic and preclinical work through to clinical and population-based learning. Next Steps Within CCaTS, next steps include creating case-based courses in regulatory and team science to continue to allow scholars to learn and apply these critical skills to real-world material. The goal is to continue to provide immersive training opportunities in areas of clinical and translational science that cannot be readily learned in a traditional lecture-based class setting.
HCN1mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond
Marini, Carla , Porro, Alessandro , Rastetter, Agnès, Dalle, Carine, Rivolta, Ilaria , Bauer, Daniel , Oegema, Renske , Nava, Caroline , Parrini, Elena , Mei, Davide , Mercer, Catherine , Dhamija, Radhika , Chambers, Chelsea , Coubes, Christine, Kuentz, Paul , Julia, Sophie , Pasquier, Laurent , Dubourg, Christèle , Carré, Wilfrid , Melani, Federico , Giardino, Maria , Innes, A. Micheil , Alembik, Yves, Scheidecker, Sophie , Figueiroa, Sónia, Garrido, Cristina , Fusco, Carlo , Spagnoli, Carlotta , Binda, Anna , Granata, Tiziana , Ragona, Francesca , Freri, Elena , Franceschetti, Silvana , Canafoglia, Laura , Castellotti, Barbara , Gellera, Cinzia , Milanesi, Raffaella , Mancardi, Maria Margherita , Clark, Damien R, Helbig, Katherine L. , Ichikawa, Shoji , Sadler, Laurie S. , Neupauerová, Jana, Laššuthová, Petra , Štěrbová, Katalin , Laridon, Annick, Brilstra, Eva H. , Koeleman, Bobby P.C. , Striano, Pasquale, Soblet, Julie , Deconinck, Nicolas , Leguern, Éric , Guerrini, Renzo , Santoro, Bina , Hamacher, Kay , Moroni, Anna , DiFrancesco, Jacopo C. , Depienne, Christel , Guerrini, Renzo , Mei, Davide , Pasquier, Laurent , Thévenon, Julien , Rosati, Anna Maria , Pisano, Tiziana , Santos, Manuela M. , Frattini, Daniele , Clark, Damien R., Kok, Fernando , Lemke, Johannes R. , Zara, Federico , Smits, Guillaume , Barbuti, Andrea , DiFrancesco, Dario , Thiel, Gerhard , Depienne, Christel , Dhamija, Radhika

Mayo Clinic

Brain | September 26, 2018 | Volume: 141 | Issue: 11 | Pages: 3160-3178

10.1093/brain/awy263 | PMID 30351409 Get It

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease
Preische, Oliver, Sohrabi, Hamid R. , Gräber, Susanne, Ringman, John M. , Martins, Ralph N. , Rossor, Martin N. , Fox, Nick N., Graff‐Radford, Neill R. , Xiong, Chengjie , Danek, Adrian , Vöglein, Jonathan , Salloway, Stephen , Xiong, Chengjie , Benzinger, Tammie L.S. , Buckles, Virginia, Masters, Colin L. , Bateman, Randall J. , Morris, John C. , Laske, Christoph , (DIAN), Dominantly Inherited Alzheimer Network, Fox, Nick C. , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Morris, John C , Müller, Stephan, Jucker, Mathias , McDade, Eric , Schofield, Peter R. , Ghetti, Bernardino , Fox, Nick N., Sperling, Reisa Anne , (DIAN), Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | September 25, 2018 | Volume: 14 | Issue: 11 | Pages: 1427-1437

10.1016/j.jalz.2018.06.3059 | PMID 30266303 Get It

AbstractIntroductionLittle is known about effects of physical activity (PA) in genetically driven early‐onset autosomal dominant Alzheimer's disease (AD).MethodsA total of 372 individuals participating at the Dominantly Inherited Alzheimer Network study were examined to evaluate the cross‐sectional relationship of PA with cognitive performance, functional status, cognitive decline, and AD biomarkers in cerebrospinal fluid. Mutation carriers were categorized as high or low exercisers according to WHO recommendations.ResultsMutation carriers with high PA showed significantly better cognitive and functional performance and significantly less AD‐like pathology in cerebrospinal fluid than individuals with low PA. Mutation carriers with high PA scored 3.4 points better on Mini Mental State Examination at expected symptom onset and fulfilled the diagnosis of very mild dementia 15.1 years later compared with low exercisers.DiscussionThese results support a beneficial effect of PA on cognition and AD pathology even in individuals with genetically driven autosomal dominant AD.
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, Taku , Kim, Sunghee , Pieper, Karen S. , Blanco, Rosalia , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Mahaffey, Kenneth W. , Singer, Daniel E. , Piccini, Jonathan P. , Steinberg, Benjamin A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Freeman, James V. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

Heart | September 18, 2018 | Volume: 105 | Issue: 5 | Pages: 370-377

10.1136/heartjnl-2018-313642 | PMID 30228248 Get It

Objective The association with B-type natriuretic peptide (BNP), disease progression and outcomes in patients with atrial fibrillation (AF) has not been thoroughly investigated. Methods We evaluated the association between BNP levels and outcomes, including AF progression, composite outcome of major adverse cardiovascular or neurological events (MACNE) and major bleeding, via pooled logistic regression and Cox frailty models in Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry. AF progression was defined as either paroxysmal becoming persistent or permanent, or persistent becoming permanent at any follow-up. Results Among 13 375 patients with AF, 2797 with BNP values at baseline (median age (IQR), 72.0 (63.0–80.0) years; 43.0% women; median BNP, 238 (102–502) ng/L; 42.3% prior heart failure) were included in the models evaluating the association between BNP levels and MACNE or major bleeding. Of these, 1282 patients with paroxysmal or persistent AF at baseline were analysed in AF progression model. The likelihood of AF progression (adjusted OR, 1.11 for every 100 ng/mL; 95% CI 1.03 to 1.19) and MACNE (adjusted HR, 1.11 for every doubling in BNP values; 95% CI 1.01 to 1.22) increased with BNP concentration, while the elevated BNP values were not associated with increased risks of major bleeding. BNP values improved the risk prediction of AF progression and MACNE when added to conventional risk estimates. Conclusions BNP levels are associated with increased risk of AF progression and cardiovascular outcomes in patients with AF. Further studies are required to assess whether biomarker-based risk stratification improves patient outcomes. Clinical trial registration NCT01701817 .
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam, Jeffrey B. , Holmes, DaJuanicia N. , Thomas, Laine , Mahaffey, Kenneth W. , Kowey, Peter R. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Singer, Daniel E. , Blanco, Rosalia , Piccini, Jonathan P. , Pokorney, Sean D. , Hylek, Elaine M. , Fonarow, Gregg C. , Gersh, Bernard J. , Freeman, James V. , Naccarelli, Gerald V. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 17, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.008928 | PMID 30371218 Get It

Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) with baseline renal function and follow‐up data were included (N=9019). CKD was defined as an estimated creatinine clearance <60 mL /min. Patient characteristics were compared by CKD status, and Cox proportional hazards modeling was used to examine the association between oral anticoagulant ( OAC ) use and outcomes and antiarrhythmic drug use and outcomes stratified by CKD stages. At enrollment, 3490 (39%) patients had an estimated creatinine clearance <60 mL /min. Patients with CKD were older and had higher CHA 2 DS 2 VAS c and Anticoagulant and Risk Factors in Atrial Fibrillation (ATRIA) scores. A rhythm control strategy was selected less frequently in patients with CKD , while OAC use was lower among Stage IV and V CKD patients. After adjustment, no significant interaction was noted for OAC and CKD on all‐cause mortality ( P =0.5442) or cardiovascular death ( P =0.1233), although a trend for increased major bleeding ( P =0.0608) and stroke, systemic embolism or transient ischemic attack ( P =0.0671) was observed. No interaction was noted for antiarrhythmic drug use and CKD status on all‐cause mortality ( P =0.9706), or stroke, systemic embolism or transient ischemic attack ( P =0.4218). Conclusions Patients with atrial fibrillation and CKD are less likely to be treated with rhythm control. Patients with advanced CKD are less likely to receive OAC . Finally, outcomes with OAC in patients with advanced CKD may be materially different with higher rates of both bleeding and stroke.
Measurement of Low‐Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry
Lowenstern, Angela , Li, Shuang , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Lee, L. Veronica, Louie, Michael J. , Wang, Tracy Y., Návar, Ann Marie , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 16, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.009251 | PMID 30371214 Get It

Background The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low‐density lipoprotein cholesterol ( LDL ‐C) to identify untreated patients with LDL ‐C ≥190 mg/dL, assess lipid‐lowering therapy adherence, and consider nonstatin therapy. We sought to determine whether clinician lipid testing practices were consistent with these guidelines. Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry enrolled primary and secondary prevention patients from 140 US cardiology, endocrinology, and primary care offices in 2015 and captured demographic data, lipid treatment history, and the highest LDL ‐C level in the past 2 years. Core laboratory lipid levels were drawn at enrollment. Among 7627 patients, 2787 (36.5%) had no LDL ‐C levels measured in the 2 years before enrollment. Patients without chart‐documented LDL ‐C levels were more often women, nonwhite, uninsured, and non–college graduates (all P <0.01). Patients without prior lipid testing were less likely to receive statin treatment (72.6% versus 76.0%; P =0.0034), a high‐intensity statin (21.5% versus 24.3%; P =0.016), nonstatin lipid‐lowering therapy (24.8% versus 27.3%; P =0.037), and had higher core laboratory LDL ‐C levels at enrollment (median 97 versus 92 mg/dL; P <0.0001) than patients with prior LDL ‐C testing. Of 166 individuals with core laboratory LDL ‐C levels ≥190 mg/dL, 36.1% had no LDL ‐C measurement in the prior 2 years, and 57.2% were not on a statin at the time of enrollment. Conclusions In routine clinical practice, LDL ‐C testing is associated with higher‐intensity lipid‐lowering treatment and lower achieved LDL ‐C levels.
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Kim, Sunghee , Go, Alan S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Singer, Daniel E. , Thomas, Laine , Blanco, Rosalia , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and, Jackson, Larry R. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and

Mayo Clinic

Journal of the American Heart Association | September 14, 2018 | Volume: 7 | Issue: 16 | Pages: No page available

10.1161/jaha.118.008764 | PMID 30369317 Get It

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these “low‐risk” patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low‐risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P <0.0001). Stroke rates were low overall and ranged from 0 per 100 patient‐years in those with CHA 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5–1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4–1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6–1.9]) in CHA 2 DS 2 VASc ≥2. All‐cause mortality (per 100 patient‐years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8–2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1–1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7–1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4–6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0‐1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0‐1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.
The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines
Chang, Albert J. , McBride, Sean M. , Keyes, Mira , Chung, Hans T. , Cox, Brett, Demanes, D. Jeffrey, Hsu, I.-Chow, Krauss, Daniel , Orio, Peter F. , Roach, Mack , Venkat, Puja , Vigneault, Éric , McBride, Sean, Davis, Brian J. , Cox, Brett W, Crook, Juanita , Demanes, David J, Kamrava, Mitchell, Krauss, Daniel J, Morton, Gerard , Orio Iii, Peter F, Roach Iii, Mack, Venkat, Puja S, Zeléfsky, Michael J. , Kamrava, Mitchell R.

Mayo Clinic

Journal of Clinical Oncology | September 13, 2018 | Volume: 36 | Issue: 33 | Pages: 3342-3344

10.1200/jco.18.00626 | PMID 30212298 Get It